产品
编 号：F450560
分子式：C19H21N3O5
分子量：371.39
分子式：C19H21N3O5
分子量：371.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
140
In-stock
5mg
279
In-stock
10mg
447
In-stock
50mg
1637
In-stock
100mg
2828
In-stock
结构图
CAS No: 75695-93-1
产品详情
生物活性：
Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease.
体内研究：
Isradipine (0.1~3 mg/kg; p.o.) makes sodium excretion increase in a dose-dependent manner.Isradipine pre-treatment reduces 6-hydroxydopamine induced neurotoxicity at the striatal level. Protective effect of isradipine at the striatal level is dose-dependent as shown from 6 mice. Isradipine pre-treatment increases the number of surviving SNc DA cells after 6-hydroxydopamine induced degeneration. Isradipine is capable of protecting striatal dopaminergic terminals and SNc dopaminergic cell bodies against a slow, progressive insult created by intrastriatal injection of 6-hydroxydopamine.Animal Model:Rats
Dosage:0.1~3 mg/kg
Administration:P.o.
Result:Sodium excretion increased in a dose-dependent manner.?
体外研究：
Isradipine has much higher (＞40 fold) affinity for Cav1.3 channels as well as good brain bioavailability. Isradipine has nearly equal potency at Cav1.2 and Cav1.3 channels.
Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease.
体内研究：
Isradipine (0.1~3 mg/kg; p.o.) makes sodium excretion increase in a dose-dependent manner.Isradipine pre-treatment reduces 6-hydroxydopamine induced neurotoxicity at the striatal level. Protective effect of isradipine at the striatal level is dose-dependent as shown from 6 mice. Isradipine pre-treatment increases the number of surviving SNc DA cells after 6-hydroxydopamine induced degeneration. Isradipine is capable of protecting striatal dopaminergic terminals and SNc dopaminergic cell bodies against a slow, progressive insult created by intrastriatal injection of 6-hydroxydopamine.Animal Model:Rats
Dosage:0.1~3 mg/kg
Administration:P.o.
Result:Sodium excretion increased in a dose-dependent manner.?
体外研究：
Isradipine has much higher (＞40 fold) affinity for Cav1.3 channels as well as good brain bioavailability. Isradipine has nearly equal potency at Cav1.2 and Cav1.3 channels.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备